Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emavusertib - Aurigene Oncology/Curis

Next Previous
Drug Profile

Emavusertib - Aurigene Oncology/Curis

Alternative Names: AU 4948; CA 4948

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Curis; University of Leipzig
  • Class Amides; Amines; Antianaemics; Antineoplastics; Antirheumatics; Morpholines; Oxazoles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; IRAK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Non-Hodgkin's lymphoma; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia; B-cell leukaemia; Chronic lymphocytic leukaemia
  • Phase I/II Acute myeloid leukaemia; Malignant melanoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Phase I Biliary cancer; Gastric cancer; Oesophageal cancer
  • Preclinical Rheumatoid arthritis
  • No development reported Adenocarcinoma

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for preclinical development in Adenocarcinoma in USA (PO)
  • 27 Mar 2026 Phase-I clinical trials in Biliary cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in USA (PO) (NCT07107750)
  • 19 Mar 2026 Curis terminates a phase-I/II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Monotherapy, Combination therapy, Second-line therapy or greater) in Italy, Israel, Germany, Poland, Spain, USA, Czech Republic and France (PO) as the dosing completed in all cohorts (NCT04278768)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top